Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor–Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis
暂无分享,去创建一个
A. Collier | M. Saunders | G. Wandeler | L. Bonnett | V. Johnston | N. Paton | M. Boyd | A. Geretti | L. Ciaffi | K. Stafford | A. Stockdale | A. Schoffelen
[1] Diederick E Grobbee,et al. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study. , 2017, The Lancet. Infectious diseases.
[2] C. Gilks,et al. Second-line antiretroviral therapy: so much to be done. , 2017, The lancet. HIV.
[3] Edward J Mills,et al. Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis. , 2017, The lancet. HIV.
[4] G. Maartens,et al. Resistance matters in EARNEST. , 2017, The lancet. HIV.
[5] T. F. Rinke de Wit,et al. Emergence of untreatable, multidrug-resistant HIV-1 in patients failing second-line therapy in Kenya , 2017, AIDS.
[6] P. Easterbrook,et al. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial , 2017, The lancet. HIV.
[7] R. Shafer,et al. Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study , 2016, The Lancet. Infectious diseases.
[8] M. Fox,et al. Treatment outcomes of over 1000 patients on second‐line, protease inhibitor‐based antiretroviral therapy from four public‐sector HIV treatment facilities across Johannesburg, South Africa , 2016, Tropical medicine & international health : TM & IH.
[9] T. F. Rinke de Wit,et al. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. , 2016, The Journal of antimicrobial chemotherapy.
[10] T. F. Rinke de Wit,et al. Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa. , 2016, The Journal of infectious diseases.
[11] M. Fox,et al. Intensive adherence counselling for HIV‐infected individuals failing second‐line antiretroviral therapy in Johannesburg, South Africa , 2016, Tropical medicine & international health : TM & IH.
[12] G. Maartens,et al. Random lopinavir concentrations predict resistance on lopinavir-based antiretroviral therapy. , 2016, International journal of antimicrobial agents.
[13] D. Cooper,et al. Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study. , 2016, AIDS research and human retroviruses.
[14] M. Peeters,et al. Short Communication: High Viral Load and Multidrug Resistance Due to Late Switch to Second-Line Regimens Could Be a Major Obstacle to Reach the 90-90-90 UNAIDS Objectives in Sub-Saharan Africa. , 2016, AIDS research and human retroviruses.
[15] J. Mellors,et al. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study. , 2016, The lancet. HIV.
[16] R. Redfield,et al. HIV drug Resistance Mutations among Patients Failing Second-Line Antiretroviral Therapy in Rwanda , 2016, Antiviral therapy.
[17] N. Ford,et al. The need for second-line antiretroviral therapy in adults in sub-Saharan Africa up to 2030: a mathematical modelling study. , 2016, The lancet. HIV.
[18] J. Farrar,et al. High prevalence of PI resistance in patients failing second-line ART in Vietnam , 2015, The Journal of antimicrobial chemotherapy.
[19] S. Sundar,et al. Outcome of patients on second line antiretroviral therapy under programmatic condition in India , 2015, BMC Infectious Diseases.
[20] E. Delaporte,et al. Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa , 2015, AIDS.
[21] T. F. Rinke de Wit,et al. Long-term Virological Outcomes of First-Line Antiretroviral Therapy for HIV-1 in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] M. Egger,et al. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis. , 2015, The lancet. HIV.
[23] J. Xie,et al. Week 120 Efficacy of Tenofovir, Lamivudine and Lopinavir/r-Based Second-Line Antiretroviral Therapy in Treatment-Experienced HIV Patients , 2015, PLoS ONE.
[24] D. Cooper,et al. Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection , 2015, PloS one.
[25] Ning Li,et al. Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials , 2015, Scientific Reports.
[26] K. Ruxrungtham,et al. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. , 2015, The lancet. HIV.
[27] N. Ford,et al. Interventions to promote adherence to antiretroviral therapy in Africa: a network meta-analysis. , 2014, The lancet. HIV.
[28] P. Easterbrook,et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. , 2014, The New England journal of medicine.
[29] R. Redfield,et al. Long-Term Outcome of Second-Line Antiretroviral Therapy in Resource-Limited Settings , 2014, Journal of the International Association of Providers of AIDS Care.
[30] A. Phillips,et al. Viral Suppression Following Switch to Second-line Antiretroviral Therapy: Associations With Nucleoside Reverse Transcriptase Inhibitor Resistance and Subtherapeutic Drug Concentrations Prior to Switch , 2013, The Journal of infectious diseases.
[31] I. Adewole,et al. Optimizing Treatment Switch for Virologic Failure during First-Line Antiretroviral Therapy in Resource-Limited Settings , 2013, Journal of the International Association of Providers of AIDS Care.
[32] D. Cooper,et al. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferio , 2013, The Lancet.
[33] A. Wensing,et al. Sustained Virological Response on Second-Line Antiretroviral Therapy following Virological Failure in HIV-Infected Patients in Rural South Africa , 2013, PloS one.
[34] Till Bärnighausen,et al. Increases in Adult Life Expectancy in Rural South Africa: Valuing the Scale-Up of HIV Treatment , 2013, Science.
[35] V. Calvez,et al. Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting. , 2012, The Journal of antimicrobial chemotherapy.
[36] O. Laeyendecker,et al. Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. , 2012, AIDS research and human retroviruses.
[37] J. Nachega,et al. Second-Line Antiretroviral Therapy: Long-Term Outcomes in South Africa , 2012, Journal of acquired immune deficiency syndromes.
[38] M. Egger,et al. Tenofovir in Second-Line ART in Zambia and South Africa: Collaborative Analysis of Cohort Studies , 2012, Journal of acquired immune deficiency syndromes.
[39] T. F. Rinke de Wit,et al. Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa. , 2012, The Journal of infectious diseases.
[40] T. F. Rinke de Wit,et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[41] A. Phillips,et al. Second-Line Antiretroviral Therapy in a Workplace and Community-Based Treatment Programme in South Africa: Determinants of Virological Outcome , 2012, PloS one.
[42] K. Freedberg,et al. Virologic Failure of Protease Inhibitor-Based Second-Line Antiretroviral Therapy without Resistance in a Large HIV Treatment Program in South Africa , 2012, PloS one.
[43] A. Wensing,et al. Accumulation of Drug Resistance and Loss of Therapeutic Options Precede Commonly Used Criteria for Treatment Failure in HIV-1 Subtype-C-Infected Patients , 2012, Antiviral therapy.
[44] T. F. Rinke de Wit,et al. Unnecessary Antiretroviral Treatment Switches and Accumulation of HIV Resistance Mutations; Two Arguments for Viral Load Monitoring in Africa , 2011, Journal of acquired immune deficiency syndromes.
[45] L. Ferradini,et al. High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia , 2011, Journal of the International AIDS Society.
[46] J. Mellors,et al. Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa , 2010, AIDS research and treatment.
[47] J. Eron,et al. Second‐line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline * , 2010, HIV medicine.
[48] N. Parkin,et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy , 2009, AIDS.
[49] M. Kamya,et al. Three-Year Outcome Data of Second-Line Antiretroviral Therapy in Ugandan Adults: Good Virological Response but High Rate of Toxicity , 2009, Journal of the International Association of Physicians in AIDS Care.
[50] Tommy F. Liu,et al. Web resources for HIV type 1 genotypic-resistance test interpretation. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[51] Rebecca Hoh,et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. , 2005, The Journal of infectious diseases.
[52] Steven C Johnson,et al. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[53] G. Smith,et al. Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.
[54] G. Robbins,et al. Partner-based adherence intervention for second-line antiretroviral therapy (ACTG A5234): a multinational randomised trial. , 2015, The lancet. HIV.
[55] L. Ferradini,et al. HIV-1 Protease Inhibitors Resistance Profiles in Patients with Virological Failure on LPV/r-based 2nd Line Regimen in Cambodia , 2013 .
[56] D. Schopflocher,et al. Development of a quality appraisal tool for case series studies using a modified Delphi technique , 2012 .
[57] J. Higgins. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .
[58] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.